Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 2754542, 6 pages
http://dx.doi.org/10.1155/2016/2754542
Research Article

Treatment of Huge Hepatocellular Carcinoma Using Cinobufacini Injection in Transarterial Chemoembolization: A Retrospective Study

1Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2Department of Integrative Oncology, Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai 200433, China
3Department of Radiology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China

Received 18 December 2015; Revised 28 March 2016; Accepted 20 April 2016

Academic Editor: Yuewen Gong

Copyright © 2016 Jun Dong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. H. Kim, M. S. Kim, J. S. Chang, K. H. Han, Y. Kim do, and J. Seong, “Therapeutic benefit of radiotherapy in huge (>10) cm unresectable hepatocellular carcinoma,” Liver International, vol. 34, no. 5, pp. 784–794, 2014. View at Google Scholar
  2. Y. W. Min, J. H. Lee, G.-Y. Gwak et al., “Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching,” Journal of Gastroenterology and Hepatology, vol. 29, no. 5, pp. 1043–1048, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. J. D. Yang and L. R. Roberts, “Hepatocellular carcinoma: a global view,” Nature Reviews Gastroenterology & Hepatology, vol. 7, no. 8, pp. 448–458, 2010. View at Google Scholar
  4. I. Bargellini, R. Sacco, E. Bozzi et al., “Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study,” European Journal of Radiology, vol. 81, no. 6, pp. 1173–1178, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. Y.-H. Huang, J.-C. Wu, S.-C. Chen et al., “Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter,” Alimentary Pharmacology & Therapeutics, vol. 23, no. 1, pp. 129–135, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. R. T.-P. Poon, H. Ngan, C.-M. Lo, C.-L. Liu, S.-T. Fan, and J. Wong, “Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence,” Journal of Surgical Oncology, vol. 73, no. 2, pp. 109–114, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Marelli, R. Stigliano, C. Triantos et al., “Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies,” CardioVascular and Interventional Radiology, vol. 30, no. 1, pp. 6–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Meng, C. R. Garrett, Y. Shen et al., “Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas,” British Journal of Cancer, vol. 107, no. 3, pp. 411–416, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. Q. Li, B. Sun, and Y. Peng, “Clinical study on the treatment of primary liver cancer by cinobufotain combined with transcatheter arterial chemoembolization,” Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai, vol. 22, no. 2, pp. 32–34, 2008. View at Google Scholar
  10. S. Ye, “Expert consensus on the scheme of pathological diagnosis of primary liver cancer,” Zhonghua Gan Zang Bing Za Zhi, vol. 17, no. 6, pp. 403–410, 2009. View at Google Scholar
  11. R. Lencioni and J. M. Llovet, “Modified recist (mRECIST) assessment for hepatocellular carcinoma,” Seminars in Liver Disease, vol. 30, no. 1, pp. 52–60, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Bruix and M. Sherman, “Management of hepatocellular carcinoma: an update,” Hepatology, vol. 53, no. 3, pp. 1020–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, “EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma,” Journal of Hepatology, vol. 56, no. 4, pp. 908–943, 2011. View at Google Scholar
  14. C. Cammà, F. Schepis, A. Orlando et al., “Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials,” Radiology, vol. 224, no. 1, pp. 47–54, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. H. Su, X. Q. Huang, D. Z. Zhang et al., “HPLC separation and determination of bufadienolide in cinobufacini injection,” Chinease Traditional Patent Medicines, vol. 25, no. 1, pp. 24–27, 2003. View at Google Scholar
  16. F. Qi, A. Li, Y. Inagaki et al., “Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor,” International Immunopharmacology, vol. 11, no. 3, pp. 342–349, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. X. D. Zuo, Y. A. Cui, and S. Qin, “Effect of cinobufacini on tumor cell cycle and expression of bcl-2 protein,” Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 12, no. 6, pp. 567–568, 2003. View at Google Scholar
  18. Q. Wu, W.-D. Lin, G.-Q. Liao, L.-G. Zhang, S.-Q. Wen, and J.-Y. Lin, “Antiproliferative effects of cinobufacini on human hepatocellular carcinoma HepG2 cells detected by atomic force microscopy,” World Journal of Gastroenterology, vol. 21, no. 3, pp. 854–861, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Qi, A. Li, Y. Inagaki et al., “Induction of apoptosis by cinobufacini preparation through mitochondria- and Fas-mediated caspase-dependent pathways in human hepatocellular carcinoma cells,” Food and Chemical Toxicology, vol. 50, no. 2, pp. 295–302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. Meng, P. Yang, Y. Shen et al., “Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer,” Cancer, vol. 115, no. 22, pp. 5309–5318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Xie, X. Huang, J. Li et al., “Efficacy and safety of Huachansu combined with chemotherapy in advanced gastric cancer: a meta-analysis,” Medical Hypotheses, vol. 81, no. 2, pp. 243–250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. X.-F. Zhai, Z. Chen, B. Li et al., “Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial,” Journal of Integrative Medicine, vol. 11, no. 2, pp. 90–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. Z. Chen, X. F. Zhai, Y. H. Su et al., “Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer,” Zhong Xi Yi Jie He Xue Bao, vol. 11, no. 1, pp. 184–186, 2003. View at Google Scholar
  24. M. Omata, L. A. Lesmana, R. Tateishi et al., “Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma,” Hepatology International, vol. 4, no. 2, pp. 439–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. X. Wang, N. Wang, F. Cheung, L. Lao, C. Li, and Y. Feng, “Chinese medicines for prevention and treatment of human hepatocellular carcinoma: current progress on pharmacological actions and mechanisms,” Journal of Integrative Medicine, vol. 13, no. 3, pp. 142–164, 2015. View at Publisher · View at Google Scholar · View at Scopus